Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0D1SG
|
|||
| Former ID |
DIB011425
|
|||
| Drug Name |
Prednisolone
|
|||
| Synonyms |
Nanocort; Prednisolone (injectable liposome formulation, rheumatoid arthritis); Prednisolone (injectable liposome formulation, rheumatoid arthritis), Enceladus; Prednisolone (injectable liposome formulation, rheumatoid arthritis), Galapagos
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Solid tumour/cancer [ICD-11: 2A00-2F9Z; ICD-10: C76-C80; ICD-9: 140-229] | Approved | [1] | |
| Multiple sclerosis [ICD-11: 8A40; ICD-9: 340] | Phase 3 | [2], [3] | ||
| Therapeutic Class |
Anticancer Agents
|
|||
| Company |
Schering Corp Sub Schering Plough Corp
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C21H28O5
|
|||
| Canonical SMILES |
CC12CC(C3C(C1CCC2(C(=O)CO)O)CCC4=CC(=O)C=CC34C)O
|
|||
| InChI |
1S/C21H28O5/c1-19-7-5-13(23)9-12(19)3-4-14-15-6-8-21(26,17(25)11-22)20(15,2)10-16(24)18(14)19/h5,7,9,14-16,18,22,24,26H,3-4,6,8,10-11H2,1-2H3/t14-,15-,16-,18+,19-,20-,21-/m0/s1
|
|||
| InChIKey |
OIGNJSKKLXVSLS-VWUMJDOOSA-N
|
|||
| CAS Number |
CAS 50-24-8
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID |
9573, 74674, 75254, 7847538, 7980377, 8153532, 10321429, 11466302, 11467422, 11486103, 12012573, 12146616, 14876794, 14876795, 24870351, 24898079, 24898725, 26697414, 29224791, 46504847, 46519223, 47500929, 47647896, 47945232, 48244811, 48414366, 48416460, 49698415, 49857644, 50085972, 50124371, 50643467, 53790825, 56311149, 56312886, 56313992, 56463372, 57288815, 57650843, 81093218, 85300842, 85788424, 87574796, 92125114, 92309181, 92710510, 93576750, 103189031, 103913923, 104169971
|
|||
| ChEBI ID |
CHEBI:8378
|
|||
| ADReCS Drug ID | BADD_D01831 | |||
| Interaction between the Drug and Microbe | Top | |||
|---|---|---|---|---|
| The Metabolism of Drug Affected by Studied Microbe(s) | ||||
| The Order in the Taxonomic Hierarchy of the following Microbe(s): Gut microbiota | ||||
| Studied Microbe: Gut microbiota unspecific | [4] | |||
| Metabolic Reaction | Reduction | |||
| Experimental Method | High-throughput screening | |||
| Description | Prednisolone can be metabolized by gut microbiota through reduction. | |||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Glucocorticoid receptor (NR3C1) | Target Info | Modulator | [5] |
| KEGG Pathway | Neuroactive ligand-receptor interaction | |||
| NetPath Pathway | IL2 Signaling Pathway | |||
| TCR Signaling Pathway | ||||
| Pathway Interaction Database | Regulation of nuclear SMAD2/3 signaling | |||
| Signaling events mediated by HDAC Class II | ||||
| FOXA2 and FOXA3 transcription factor networks | ||||
| Glucocorticoid receptor regulatory network | ||||
| Regulation of Androgen receptor activity | ||||
| AP-1 transcription factor network | ||||
| Reactome | BMAL1:CLOCK,NPAS2 activates circadian gene expression | |||
| WikiPathways | Serotonin Receptor 4/6/7 and NR3C Signaling | |||
| SIDS Susceptibility Pathways | ||||
| Nuclear Receptors Meta-Pathway | ||||
| Endoderm Differentiation | ||||
| Hair Follicle Development: Cytodifferentiation (Part 3 of 3) | ||||
| Adipogenesis | ||||
| Circadian Clock | ||||
| Nuclear Receptors | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015 | |||
| REF 2 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 2866). | |||
| REF 3 | ClinicalTrials.gov (NCT02534896) To Evaluate The Efficacy And Safety Of Intravenous Pegylated Liposomal Prednisolone Sodium Phosphate (Nanocort) Compared With Intramuscular Injection Of Methylprednisolone Acetate In Subjects With Active Rheumatoid Arthritis. | |||
| REF 4 | Personalized Mapping of Drug Metabolism by the Human Gut Microbiome. Cell. 2020 Jun 25;181(7):1661-1679.e22. | |||
| REF 5 | Aldosterone (mineralocorticoid) equivalent to prednisolone (glucocorticoid) in reversing hearing loss in MRL/MpJ-Fas1pr autoimmune mice. Laryngoscope. 2000 Nov;110(11):1902-6. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.